

ONE HUNDRED FOURTEENTH CONGRESS  
**Congress of the United States**  
**House of Representatives**  
COMMITTEE ON ENERGY AND COMMERCE  
2125 RAYBURN HOUSE OFFICE BUILDING  
WASHINGTON, DC 20515-6115  
Majority (202) 225-2927  
Minority (202) 225-3641

May 21, 2015

Dr. Douglas Throckmorton  
Deputy Director  
Center for Drug Evaluation and Research  
Food and Drug Administration  
10903 New Hampshire Avenue  
Silver Spring, MD 20993

Dear Dr. Throckmorton:


Thank you for appearing before the Subcommittee on Oversight and Investigations on Friday, May 1, 2015, to testify at the hearing entitled "What is the Federal Government Doing to Combat the Opioid Abuse Epidemic."

Pursuant to the Rules of the Committee on Energy and Commerce, the hearing record remains open for ten business days to permit Members to submit additional questions for the record, which are attached. The format of your responses to these questions should be as follows: (1) the name of the Member whose question you are addressing, (2) the complete text of the question you are addressing in bold, and (3) your answer to that question in plain text.

Also attached are Member requests made during the hearing. The format of your responses to these requests should follow the same format as your responses to the additional questions for the record.

To facilitate the printing of the hearing record, please respond to these questions and requests with a transmittal letter by the close of business on Thursday, June 4, 2015. Your responses should be mailed to Brittany Havens, Legislative Clerk, Committee on Energy and Commerce, 2125 Rayburn House Office Building, Washington, D.C. 20515 and e-mailed in Word format to [brittany.havens@mail.house.gov](mailto:brittany.havens@mail.house.gov).

Thank you again for your time and effort preparing and delivering testimony before the Subcommittee.

Sincerely,  


Tim Murphy  
Chairman  
Subcommittee on Oversight and Investigations

cc: The Honorable Diana DeGette, Ranking Member, Subcommittee on Oversight and Investigations

Attachments

## **Attachment 1—Additional Questions for the Record**

### **The Honorable Michael C. Burgess**

1. While technology has the potential to solve many problems in healthcare, we are hearing similar complaints about PDMPs as we do with EHRs. Some doctors suggest that PDMPs interrupt clinical workflow. The Health IT Policy Committee sought public comment on whether EHR certification could enable and support streamlined access to PDMPs. Because PDMPs are a critical tool for patient care and clinical decision making, ONC suggested in their September 2013 report to Congress that they would explore a PDMP requirement in certification of EHRs. Can anyone speak to further discussion regarding including PDMPs as a requirement for certification of EHRs?

### **The Honorable Larry Bucshon**

1. Can you expand a bit on your experience with Vivitrol (aka naltrexone) specifically, and how greater access could be helpful across the nation?

**Attachment 2—Member Requests for the Record**

*During the hearing, Members asked you to provide additional information for the record, and you indicated that you would provide that information. For your convenience, descriptions of the requested information are provided below.*

**The Honorable David McKinley**

1. What one thing would you recommend that we could do to try to start reversing this epidemic and this problem?